Hemophilia with Movement
We recommend
EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
Physical Activity in Young Men with Hemophilia A
What may influence the inclusion of physical activity in the lifestyle of individuals with…
N9-GP in Previously Treated Pediatric Patients with Hemophilia B – Extended Follow-up
An analysis of extended treatment with nonacog alfa pegol (N9-GP) in pediatric patients with…
Articles on this topic
Physical Activity in Hemophiliacs and How to Ensure it Safely
Physical activity is beneficial − and this holds true for patients with hemophilia as well.…
Subscribe
Most read on this topic
Related topic
Most read on this topic
- Manual Fascial Therapy in Patients with Hemophilic Arthropathy
- Physical Activity in Hemophiliacs and How to Ensure it Safely
- Physiotherapy as Part of Comprehensive Care for People with Hemophilia – Recommendations vs. Reality
- The Role of the Physiotherapist in the Management of Hemophilia – Defining a New Normal
- Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population
- Sport and Programmed Sports Therapy in Hemophiliacs
Related topic